Legal status · Australia
Is Anti-IL-11 legal in Australia?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. Anti-IL-11 is not approved for any medical use in Australia; its classification is "Investigational, not registered". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, no human study is cited on its profile.
Anti-IL-11 in Australia at a glance
| Classification | Investigational, not registered |
|---|---|
| TGA approval status | Not approved by TGA; investigational |
| Human studies cited | 0 of 1 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the Anti-IL-11 profile, checked against Therapeutic Goods Administration (TGA) listings at the reviewed date.
What this means
- 01
Anti-IL-11 is being studied in registered clinical trials but has not received TGA marketing approval in Australia.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What Anti-IL-11 is
Blocking a single inflammatory cytokine extended healthspan and lifespan in mice, and it worked when started in already old animals. No human ageing trial exists.
This is one of the more striking mouse results in recent ageing biology, and the detail that matters is when treatment started. Interleukin-11 is a cytokine in the interleukin-6 family that rises with age and drives fibrosis and inflammatory signalling.
Mechanism: Interleukin-11 signals through a receptor complex using IL-11RA and the shared gp130 subunit, activating JAK and STAT3 and also ERK signalling. It is a driver of fibroblast activation and fibrosis across organs, and its expression rises with age.
Regulatory history: No anti-IL-11 agent is approved for any indication. Recombinant IL-11 itself, oprelvekin, was previously an approved drug for thrombocytopenia, which is the opposite intervention.
How TGA treats this kind of product
Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.
The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for Anti-IL-11 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Anti-IL-11 in other countries
Frequently asked questions
Is Anti-IL-11 legal in Australia?
No. Anti-IL-11 is not approved for any medical use in Australia; its classification is "Investigational, not registered". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, no human study is cited on its profile.
Can I buy Anti-IL-11 in Australia?
No approved product exists to buy. In Australia Anti-IL-11 is classified as "Investigational, not registered", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors.
Is Anti-IL-11 TGA approved?
No. In Australia Anti-IL-11 is classified as "Investigational, not registered", which is not a TGA marketing approval. For comparison, the US FDA status is: No anti-IL-11 agent is approved for any indication. Recombinant IL-11 itself, oprelvekin, was previously an approved drug for thrombocytopenia, which is the opposite intervention.. On the evidence, no human study is cited on its profile.
Related compounds in Australia
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Anti-IL-11 live on its compound profile.
Anti-IL-11 profileThis page is general information about the regulatory status of Anti-IL-11 in Australia, current as of Sep 2026. It is not legal advice, and classifications change; check Therapeutic Goods Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.